<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Crinetics Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc</link>
<description>Latest news and press releases for Crinetics Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 21:13:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/crinetics-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835597378dffbe2df0eb0be.webp</url>
<title>Crinetics Pharmaceuticals Inc</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc</link>
</image>
<item>
<title>Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-the-european-commission-approval-of-palsonifyr-paltusotine-for-the-treatment-of-acromegaly-in-adults</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-the-european-commission-approval-of-palsonifyr-paltusotine-for-the-treatment-of-acromegaly-in-adults</guid>
<pubDate>Mon, 27 Apr 2026 21:13:00 GMT</pubDate>
<description>PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics’ first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commissio</description>
</item>
<item>
<title>Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/neutrolis-appoints-caren-deardorf-as-chief-business-and-strategy-officer</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/neutrolis-appoints-caren-deardorf-as-chief-business-and-strategy-officer</guid>
<pubDate>Wed, 15 Apr 2026 18:00:00 GMT</pubDate>
<description>Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Bus</description>
</item>
<item>
<title>Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-submission-of-marketing-authorization-application-in-brazil-for-palsonifytm-paltusotine-in-acromegaly</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-submission-of-marketing-authorization-application-in-brazil-for-palsonifytm-paltusotine-in-acromegaly</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Application supported by comprehensive clinical program, including two positive Phase 3 trials evaluating once-daily oral paltusotine in acromegaly SAN DIEGO,</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRN</description>
</item>
<item>
<title>Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-participate-two-upcoming-210500861</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-participate-two-upcoming-210500861</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management wi</description>
</item>
<item>
<title>Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-report-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-report-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year</description>
</item>
<item>
<title>Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-initiates-phase-2-3-210500098</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-initiates-phase-2-3-210500098</guid>
<pubDate>Thu, 22 Jan 2026 21:05:00 GMT</pubDate>
<description>First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAHSAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-january-2026-210500540</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-january-2026-210500540</guid>
<pubDate>Mon, 12 Jan 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Pla</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-pricing-public-022200475</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-pricing-public-022200475</guid>
<pubDate>Wed, 07 Jan 2026 02:22:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-proposed-public-offering-common-stock-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-proposed-public-offering-common-stock-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-strong-palsonify-launch-execution-and-positive-results-concurrent</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-strong-palsonify-launch-execution-and-positive-results-concurrent</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment</description>
</item>
<item>
<title>Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-provide-palsonify-business-update-and-announce-topline</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-provide-palsonify-business-update-and-announce-topline</guid>
<pubDate>Sun, 04 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and</description>
</item>
<item>
<title>Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-participate-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-participate-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and</description>
</item>
<item>
<title>Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-first-patient-dosed-pivotal-adult-trial-atumelnant-congenital-0</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-first-patient-dosed-pivotal-adult-trial-atumelnant-congenital-0</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH SAN DIEGO, Dec.</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-december-2025-inducement-grants-under-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-december-2025-inducement-grants-under-nasdaq</guid>
<pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation</description>
</item>
<item>
<title>Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-first-patient-dosed-phase-1-2-trial-evaluating-crn09682-0</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-first-patient-dosed-phase-1-2-trial-evaluating-crn09682-0</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics</description>
</item>
<item>
<title>Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-first-patient-randomized-pivotal-phase-3-carefndr-trial</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-announces-first-patient-randomized-pivotal-phase-3-carefndr-trial</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-november-2025-inducement-grants-under-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-announces-november-2025-inducement-grants-under-nasdaq</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation</description>
</item>
<item>
<title>Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/crinetics-pharmaceuticals-inc/news/crinetics-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash</description>
</item>
</channel>
</rss>